Related Experiment Videos
[CD80-modified tumor cell lines: implications for cell-based vaccinations in breast cancer patients]
1Institut für Immunologie, Frauenklinik der Eberhard-Karls-Universität, Tübingen. brigitte.gueckel@uni-tuebingen.de
Abstract:
A number of genetic alterations are required for malignant transformation. However, these mutations provide the source for tumor-associated antigens which can be recognized by cellular effectors of the immune system. Recent advances in tumor immunology - such as the improved understanding of antigen presentation as well as T cell activation - have opened new perspectives for cancer immunotherapy. The advantage of using tumor cell based vaccines is that these comprise the complete antigen pool of an individual tumor for activating polyclonal immune responses. However, the induction of antigen-specific immune responses is impaired by the fact that T cell activation is depending on additional nonspecific costimulatory signals provided by the antigen-presenting cell. The majority of solid human tumors does not express costimulatory molecules and is unable to deliver all signals required for T cell activation. In contrast, tumors often induce immunologic tolerance. Therefore, the introduction of genes encoding costimulatory molecules such as CD80 or cytokines is aimed at conferring the immunostimulatory potential of tumor cells. We have undertaken efforts at endowing a breast carcinoma cell line expressing at least seven known tumor associated antigens with immunostimulatory competence by CD80 gene transfer. In preclinical studies this cell line was demonstrated to induce specific immune responses. We designed a phase I/II trial to administer the CD80-modified cell line to patients with metastatic breast cancer to determine the toxicities of the vaccination protocol and nature of the vaccine-induced immune response.
Insights
This study engineered a breast cancer vaccine using CD80 gene transfer to enhance immune responses. The modified vaccine showed potential in preclinical studies and is now in a Phase I/II trial for metastatic breast cancer patients.
Area of Science:
- Oncology
- Immunology
- Cancer Immunotherapy
Background:
- Malignant transformation involves genetic alterations, creating tumor-associated antigens recognized by the immune system.
- Advances in tumor immunology and T cell activation offer new cancer immunotherapy strategies.
- Tumor cell-based vaccines offer a complete antigen pool but face challenges in T cell activation due to lacking costimulatory signals.
Purpose of the Study:
- To enhance the immunostimulatory potential of tumor cells by introducing genes for costimulatory molecules.
- To engineer a breast carcinoma cell line with CD80 gene transfer for enhanced immune response induction.
- To evaluate the safety and immune response of a CD80-modified tumor cell vaccine in metastatic breast cancer patients.
Main Methods:
- Engineered a breast carcinoma cell line expressing seven tumor-associated antigens with CD80 gene transfer.
- Preclinical studies demonstrated the cell line's ability to induce specific immune responses.
- Designed a Phase I/II clinical trial to assess vaccine toxicity and immune response in patients.
Main Results:
- The CD80-modified breast carcinoma cell line demonstrated the ability to induce specific immune responses in preclinical studies.
- A Phase I/II trial was initiated to evaluate the safety and immunogenicity of the CD80-modified vaccine in metastatic breast cancer.
- The trial aims to determine the toxicities of the vaccination protocol and characterize the vaccine-induced immune response.
Conclusions:
- Genetic modification of tumor cells with costimulatory molecules like CD80 can enhance their immunostimulatory potential.
- The CD80-modified tumor cell vaccine shows promise for cancer immunotherapy in breast cancer.
- Further clinical evaluation is necessary to confirm the safety and efficacy of this novel vaccine approach.